Histogenics (HSGX) Stock Price Down 0.3%

Histogenics Corp (NASDAQ:HSGX)’s share price fell 0.3% during trading on Monday . The stock traded as low as $0.52 and last traded at $0.55. 16,621 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 8,245,490 shares. The stock had previously closed at $0.55.

Several research firms recently commented on HSGX. Zacks Investment Research lowered Histogenics from a “hold” rating to a “sell” rating in a research note on Wednesday. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Histogenics in a research note on Monday, August 13th. BTIG Research lowered Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 target price for the company. in a research note on Wednesday, September 5th. Finally, Needham & Company LLC boosted their price target on Histogenics to $5.00 and gave the company a “buy” rating in a research report on Thursday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Histogenics presently has a consensus rating of “Hold” and a consensus price target of $3.45.

The stock has a market cap of $16.12 million, a PE ratio of -0.57 and a beta of 1.02.

Histogenics (NASDAQ:HSGX) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.10. As a group, analysts predict that Histogenics Corp will post -0.75 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. DRW Securities LLC purchased a new stake in Histogenics during the second quarter valued at about $242,000. Renaissance Technologies LLC grew its position in Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 22,133 shares during the period. BlackRock Inc. grew its position in Histogenics by 72.0% during the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Histogenics during the first quarter valued at about $320,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Histogenics (HSGX) Stock Price Down 0.3%” was posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.wkrb13.com/2018/11/07/histogenics-hsgx-stock-price-down-0-3.html.

About Histogenics (NASDAQ:HSGX)

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Read More: Moving Average (MA)

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply